Provided by Tiger Fintech (Singapore) Pte. Ltd.

Milestone Pharmaceuticals Inc.

2.17
+0.14006.90%
Post-market: 2.11-0.0600-2.76%19:57 EDT
Volume:2.44M
Turnover:5.22M
Market Cap:115.72M
PE:-2.86
High:2.21
Open:2.15
Low:2.07
Close:2.03
Loading ...

Company Profile

Company Name:
Milestone Pharmaceuticals Inc.
Exchange:
NASDAQ
Establishment Date:
2003
Employees:
47
Office Location:
1111 Dr. Frederik-Philips Boulevard,Suite 420,Montreal,Quebec,Canada
Zip Code:
H4M 2X6
Fax:
- -
Introduction:
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Directors

Name
Position
Joseph Oliveto
President, Chief Executive Officer and Director
Debra K. Liebert
Independent Director
Michael Tomsicek
Independent Director
Paul Edick
Independent Director and Chairperson of the Board
Paul Truex
Independent Director
Richard Pasternak
Independent Director

Shareholders

Name
Position
Joseph Oliveto
President, Chief Executive Officer and Director
Amit Hasija
Chief Financial Officer and Executive Vice President of Corporate Development
Francis Plat
Chief Medical Officer
Lorenz Muller
Chief Commercial Officer